Bavarian pivoted in 2019 toward building a more traditional commercial tickborne encephalitis and dedicating its RD efforts to infectious disease and cancer vaccines. But the transition has been bumpy, in July the company dropped out of the respiratory syncytial virus vaccine race after a Phase 3 trial failed to meet its main goal